To correlate the pharmacokinetics and toxicity of methotrexate, we measured the drug's clearance from plasma after 395 high-dose, six-hour infusions given to 78 patients. After 375 infusions, 48 hour methotrexate levels fell within 2 standard deviations of the mean for nontoxic infusions, and myelosuppression did not occur. Methotrexate concentrations exceeded the range for nontoxic patients (mean +/- 2 standard deviations) after 20 infusions. Serious myelosuppression occurred after six of these 20 infusions, including five of 12 infusions associated with 48-hour drug concentrations above 9 X 10(-7) M. In seven patients with 48-hour concentrations above 9 X 10(-7) M, the absence of toxicity could be attributed to subsequent rapid clearance of the drug; four of these patients also received large doses of supplemental leucovorin (50 to 100 mg per square meter every six hours). Determination of methotrexate concentration in plasma thus identified patients at high risk of toxicity, a group that may benefit from supplemental leucovorin rescue.
This article has been cited by other articles:
Saleem, A., Price, P. M.
(2008). Early Tumor Drug Pharmacokinetics Is Influenced by Tumor Perfusion but not Plasma Drug Exposure. Clin. Cancer Res.
14: 8184-8190
[Abstract][Full Text]
Phillips, M., Smith, W., Balan, G., Ward, S.
(2008). Pharmacokinetics of Glucarpidase in Subjects With Normal and Impaired Renal Function. J Clin Pharmacol
48: 279-284
[Abstract][Full Text]
Snyder, R. L.
(2007). Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use. Am J Health Syst Pharm
64: 1163-1169
[Abstract][Full Text]
Widemann, B. C., Adamson, P. C.
(2006). Understanding and managing methotrexate nephrotoxicity.. The Oncologist
11: 694-703
[Abstract][Full Text]
Parshuram, C. S, Dupuis, L L., To, T., Weitzman, S. S, Koren, G., Laupacis, A.
(2006). Occurrence and Impact of Unanticipated Variation in Intravenous Methotrexate Dosing. The Annals of Pharmacotherapy
40: 805-811
[Abstract][Full Text]
Robien, K.
(2005). Folate During Antifolate Chemotherapy: What We Know... and Do Not Know. Nutr Clin Pract
20: 411-422
[Abstract][Full Text]
Lam, M. S H, Ignoffo, R. J
(2003). A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract
9: 45-85
[Abstract]
Collins, J. M.
(2000). Cytochrome P-450 and Other Determinants of Pharmacokinetics, Toxicity, and Efficacy in Humans. Clin. Cancer Res.
6: 1203-1204
[Full Text]
Aghi, M., Kramm, C. M., Breakefield, X. O.
(1999). Folylpolyglutamyl Synthetase Gene Transfer and Glioma Antifolate Sensitivity in Culture and In Vivo. JNCI J Natl Cancer Inst
91: 1233-1241
[Abstract][Full Text]
Flombaum, C. D., Meyers, P. A.
(1999). High-Dose Leucovorin as Sole Therapy for Methotrexate Toxicity. JCO
17: 1589-1589
[Abstract][Full Text]
Klein, P., Muggia, F. M.
(1999). Cytoprotection: Shelter from the Storm. The Oncologist
4: 112-121
[Full Text]
Widemann, B. C., Balis, F. M., Adamson, P. C.
(1999). Dihydrofolate Reductase Enzyme Inhibition Assay for Plasma Methotrexate Determination Using a 96-Well Microplate Reader. Clin. Chem.
45: 223-228
[Abstract][Full Text]
Hon, Y. Y., Evans, W. E.
(1998). Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin. Chem.
44: 388-400
[Abstract][Full Text]
Ignoffo, R. J., King, R.
(1995). Pharmaceutical care and the cancer patient. J Oncol Pharm Pract
1: 7-19
[Abstract]
Schappell, D. L., Alper, J. C., McDonald, C. J.
(1995). Treatment of Advanced Mycosis Fungoides and Sezary Syndrome With Continuous Infusions of Methotrexate Followed by Fluorouracil and Leucovorin Rescue. Arch Dermatol
131: 307-313
[Abstract]
Parke, D. V.
(1985). Adverse Effects of Drugs -- Their Causes and Prevention. The Journal of the Royal Society for the Promotion of Health
105: 39-46
Stead, A.H., Moffat, A.C.
(1983). A Collection of Therapeutic, Toxic and Fatal Blood Drug Concentrations in Man. Hum Exp Toxicol
2: 437-464
[Abstract]
BENNETT, W. M., MUTHER, R. S., PARKER, R. A., FEIG, P., MORRISON, G., GOLPER, T. A., SINGER, I.
(1980). Drug Therapy in Renal Failure: Dosing Guidelines for Adults: Part II: Sedatives, Hypnotics, and Tranquilizers; Cardiovascular, Antihypertensive, and Diuretic Agents; Miscellaneous Agents. ANN INTERN MED
93: 286-325
[Abstract]
Fischer, T. J., Rachelefsky, G. S., Klein, R. B., Paulus, H. E., Stiehm, E. R.
(1979). Childhood Dermatomyositis and Polymyositis: Treatment With Methotrexate and Prednisone. Arch Pediatr Adolesc Med
133: 386-389
[Abstract]
Previous
